二、对公司的影响及风险提示 智通财经APP讯，益佰制药(600594.SH)发布公告，近日，公司收到贵州省药品监督管理局出具的《暂 停生产、销售通知书》(黔药监生产(药化)暂停[2025]4号)。 贵州益佰制药股份有限公司：在国家药品监督管理局食品药品审核查验中心开展的检查工作中，发现你 公司存在缺陷，涉及个别记录企业未如实填写，部分电子数据未能采用可靠的方式进行记录。经国家药 监局核查中心综合评定，结论为不符合。根据国家药监局药品监管司《关于对贵州益佰制药股份有限公 司有关问题调查处理的通知》(药监药管函[2025]277号)要求，结合《贵州省药品监督管理局药品安全隐 患风险控制措施执行规则》第七条中暂停生产、销售的情形，按照《药品检查管理办法(试行)》第六十 一条之规定，现通知你单位自收到本通知后立即暂停小儿止咳糖浆生产、销售。 一、《暂停生产、销售通知书》的主要内容 公司产品小儿止咳糖浆2021年、2022年、2023年、2024年的营业收入分别为342万元、432万元、838万 元、151万元，占公司当期合并报表营业收入的比例分别为0.10%、0.16%、0.30%、0.07%，收入占比较 小。本次小 ...

Core Viewpoint - Yibai Pharmaceutical has received a suspension notice from the Guizhou Provincial Drug Administration, halting the production and sale of its children's cough syrup due to regulatory non-compliance identified during an inspection [1]. Group 1: Regulatory Actions - The suspension notice was issued following an inspection by the National Medical Products Administration, which found deficiencies in the company's record-keeping and electronic data reliability [1]. - The notice requires the company to immediately cease the production and sale of its children's cough syrup upon receipt of the notification [1]. Group 2: Financial Impact - The revenue from the children's cough syrup for the years 2021, 2022, 2023, and 2024 was reported as 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total consolidated revenue [2]. - The suspension of the children's cough syrup is expected to have a minimal impact on the company's overall performance due to the relatively small proportion of revenue generated from this product [2].

Core Viewpoint - Yibai Pharmaceutical has received a suspension notice from the Guizhou Provincial Drug Administration, leading to the halt of production and sales of its pediatric cough syrup due to regulatory non-compliance issues identified during an inspection [1] Company Summary - The suspension notice cites deficiencies such as incomplete record-keeping and unreliable electronic data recording [1] - The company has stated that the revenue contribution from the pediatric cough syrup from 2021 to 2024 is relatively small, and the suspension is not expected to significantly impact overall performance [1]

Group 1 - The stock price of Yibai Pharmaceutical closed at 4.53 yuan on August 4, down 0.02 yuan from the previous trading day, with an opening price of 4.60 yuan and a daily fluctuation range of 4.40% [1] - The company specializes in the research, development, production, and sales of traditional Chinese medicine formulations and chemical drugs, covering multiple therapeutic areas including cardiovascular, anti-tumor, and respiratory systems [1] - Yibai Pharmaceutical holds several exclusive and patented products, establishing a significant influence in the modernization of traditional Chinese medicine [1] Group 2 - On August 4, the net outflow of main funds was 18.36 million yuan, accounting for 0.51% of the circulating market value, with a cumulative net outflow of 321,400 yuan over the past five trading days, representing 0.01% of the circulating market value [1] - During the trading session, there was a rapid rebound, with a peak increase of over 2% at 9:39 AM and a transaction volume of 44.55 million yuan [1]

Group 1 - The core viewpoint of the news is that Yibai Pharmaceutical (益佰制药) has shown a mixed performance in its latest financial results, with a decrease in total revenue but a significant increase in net profit [1] - As of August 1, 2025, Yibai Pharmaceutical's stock price closed at 4.55 yuan, reflecting a 3.64% increase, with a trading volume of 568,200 lots and a transaction amount of 258 million yuan [1] - The company's latest quarterly report indicates total revenue of 501 million yuan, a year-on-year decrease of 12.43%, while net profit attributable to shareholders reached 9.39 million yuan, a year-on-year increase of 86.29% [1] Group 2 - The company has a current ratio of 1.843, a quick ratio of 1.195, and a debt-to-asset ratio of 35.05%, indicating a stable liquidity position [1] - Yibai Pharmaceutical has made investments in 27 companies and participated in 2,883 bidding projects, showcasing its active engagement in the market [2] - The company holds 412 trademark registrations and 365 patents, along with 360 administrative licenses, reflecting its strong intellectual property portfolio [2]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts a loss for the first half of 2025, with a significant narrowing of the loss compared to the same period last year, projecting net profit attributable to shareholders between -21.24 million CNY and -17.70 million CNY, based on unaudited preliminary results Key Financial Indicators Forecast | Indicator | Estimated Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -21.24 million to -17.70 million | | Net Profit After Non-Recurring Gains and Losses | -33.36 million to -27.80 million | - This performance forecast is unaudited by a certified public accountant[4](index=4&type=chunk) [Operating Performance and Financial Status for the Same Period Last Year](index=1&type=section&id=II.%20Operating%20Performance%20and%20Financial%20Status%20for%20the%20Same%20Period%20Last%20Year) For comparison, the company reported a net loss of -106.49 million CNY and a non-recurring adjusted net loss of -111.54 million CNY for the first half of 2024, with basic earnings per share at -0.134 CNY Key Financial Indicators for H1 2024 | Indicator | H1 2024 Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -106.49 million | | Net Profit After Non-Recurring Gains and Losses | -111.54 million | | Earnings Per Share | -0.134 | [Primary Reasons for Current Period's Expected Loss](index=2&type=section&id=III.%20Primary%20Reasons%20for%20Current%20Period's%20Expected%20Loss) The core reason for the continued loss is a 15% projected decrease in revenue due to reduced sales of main products, yet effective cost and expense control, with an estimated 20% reduction, has narrowed the overall loss compared to the prior year - The primary reason for the expected loss is the impact of core business operations, with main product sales decreasing, leading to an estimated **15% decline in revenue**[7](index=7&type=chunk) - Despite the revenue decline, costs and expenses decreased more significantly, with an estimated **20% reduction**, resulting in a smaller loss for the current period compared to the prior year[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) The company emphasizes that this performance forecast is based on preliminary internal calculations and is unaudited, but confirms no significant uncertainties affect its accuracy - This performance forecast is a preliminary calculation by the company's finance department and has not yet been audited[8](index=8&type=chunk) - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[8](index=8&type=chunk) [Other Explanatory Matters](index=2&type=section&id=V.%20Other%20Explanatory%20Matters) The company reminds investors that the final accurate financial data will be based on the officially disclosed 2025 semi-annual report, and advises caution regarding investment risks - The final financial data will be subject to the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)